Rishi M, Kaur J, Ulanja M, Manasewitsch N, Svendsen M, Abdalla A, Vemala S, Kewanyama J, Singh K, Singh N, Gullapalli N, Osgard E. Randomized, double-blinded, placebo-controlled trial evaluating simethicone pretreatment with bowel preparation during colonoscopy. World J Gastrointest Endosc 2019; 11(6): 413-423 [PMID: 31236194 DOI: 10.4253/wjge.v11.i6.413]
Corresponding Author of This Article
Mohit Rishi, MD, Academic Research, Department of Internal Medicine, University of Nevada, Reno School of Medicine, Renown Regional Medical Center, 1155 Mill St. W11, Reno, NV 89502, United States. mrishi@unr.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. Jun 16, 2019; 11(6): 413-423 Published online Jun 16, 2019. doi: 10.4253/wjge.v11.i6.413
Table 1 Inclusion and exclusion criteria
Inclusion
Exclusion
Male and female patients between 18-80 yr old
Patients under 18 or over 80 yr old
Outpatient, elective colonoscopies
Severe constipation
Patients using Gatorade-Polyethylene Glycol 3350-Bisacodyl bowel prep
Suspected bowel perforation or obstruction
Uncontrolled hypertension
Urgent/emergent colonoscopies
History of bowel resection
Allergy to simethicone
Table 2 Adverse events, n (%)
Simethicone, n = 84
Placebo, n = 84
Abdominal pain/Cramping
10 (8)
12 (14)
Nausea
13 (15)
20 (24)
Vomiting
4 (5)
6 (7)
Serious adverse events
Rash
1 (1)
1 (1)
Itching
1 (1)
None
Table 3 Inter-observer variability
Intraluminal bubbles grade
Kappa value
P-value
1
0.5687
< 0.001
2
0.2605
< 0.001
3
0.3481
< 0.001
4
0.5440
< 0.001
Combined
0.4024
< 0.001
Table 4 Demographics, Intraluminal Bubble Scale, and Boston Bowel Preparation Scale characteristics, n (%)
Simethicone
Placebo
P-value
Baseline characteristics
Gender
0.436
Female
50 (59.5)
45 (53.6)
Male
34 (40.5)
39 (46.4)
mean age (yr ± SD)
59.6 ± 14.0
54.0 ± 16.4
0.019
Median age (yr)
63 (IQR; 51-70)
57 (IQR; 43-68)
0.033
Outcomes
Intraluminal Bubbles Scale
< 0.001
1
73 (86.9)
46 (54.8)
2
7 (8.3)
18 (21.4)
3
2 (2.4)
13 (15.5)
4
2 (2.4)
7 (8.3)
Boston Bowel Prep Scale
0.832
3
2 (2.4)
1 (1.2)
4
0 (0.0)
1 (1.2)
5
2 (2.4)
1 (1.2)
6
26 (31.0)
31 (36.9)
7
13 (15.5)
13 (15.5)
8
9 (10.7)
9 (10.7)
9
32 (38.1)
27 (32.1)
Missing
0 (0.0)
1 (1.2)
Table 5 Preparation efficacy end points, n (%)
Simethicone, n = 84
Placebo, n = 84
P-value
Intraluminal Bubbles Scale
mean (± SD)
1.20 ± 0.60
1.77 ± 1.00
< 0.001
Low grade (I+II)
80 (55.6)
64 (44.4)
0.184
High grade (III + IV)
4 (16.7)
20 (83.3)
0.007
Boston Bowel Preparation Score (BBPS)
mean (± SD)
7.42 ± 1.51
7.28 ± 1.44
0.542
Mean cecal insertion time (± SD)
6.06 ± 3.55
5.48 ± 2.82
0.252
Mean withdrawal time (± SD)
11.73 ± 5.52
11.23 ± 3.99
0.500
No polyps
37 (49.3)
38 (50.7)
0.907
Total polyps
127 (56.7)
97 (43.3)
0.047
Adenomas
86 (65.6)
45 (34.4)
0.001
Sessile serrated polyps
4 (3.2)
7 (7.2)
0.163
Large polyps (> 5 mm), (mean ± SD)
1.13 ± 1.71
1.16 ± 1.27
0.937
Small polyps (1 mm - 4 mm), (mean ± SD)
1.56 ± 1.92
1.00 ± 1.14
0.093
Right sided polyps (mean ± SD)
1.23 ± 1.95
0.98 ± 0.96
0.429
Left sided polyps
1.53 ± 1.56
1.18 ± 1.19
0.228
Citation: Rishi M, Kaur J, Ulanja M, Manasewitsch N, Svendsen M, Abdalla A, Vemala S, Kewanyama J, Singh K, Singh N, Gullapalli N, Osgard E. Randomized, double-blinded, placebo-controlled trial evaluating simethicone pretreatment with bowel preparation during colonoscopy. World J Gastrointest Endosc 2019; 11(6): 413-423